Omega-3 Fatty Acids

ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia

Top

Exclusive! Expert commentary from Silvio E. Inzucchi, MD, on the ORIGIN glargine trial. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. ORIGIN: Insulin Glargine and CVD and Other Outcomes in Dysglycemia. N Engl J Med. 2012;367(4):319-328. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes

ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia

Top

Exclusive! Video commentary from Vivian A. Fonseca, MD. ORIGIN Trial Investigators, Bosch J, Gerstein HC, et al. ORIGIN: Omega-3 Fatty Acid and CVD Outcomes in Patients with Dysglycemia. N Engl J Med. 2012;367(4):309-318. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is a randomized, double-blind trial with a 2X2 factorial design that enrolled 12,537 patients who were at high risk for CV events and who had IFG, IGT, or newly diagnosed diabetes.

Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial

Top

Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes an analysis of baseline data from the ORIGIN trialRamachandran A, Riddle MC, Kabali C, Gerstein HC for the ORIGIN Investigators. Diabetes Care. 2012 35 749 753. The Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial is a global trial assessing whether targeting normal FPG levels with basal insulin glargine reduces cardiovascular outcomes compared with standard care among people taking 0 or 1 oral antidiabetes drugs (OADs).

The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient

Top

Fruchart JC, Sacks FM, Hermans MP, et al, for the Residual Risk Reduction Initiative (R3I). The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008;5(4):319-35. Despite current standards of care aimed at achieving targets for low-density lipoprotein (LDL) cholesterol, blood pressure and glycaemia, dyslipidaemic patients remain at high residual risk of vascular events.

Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia

Top

Origin Trial Investigators; Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J. 2008;155(1):26-32, 32.e1-6. Impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and diabetes arise due to insufficient insulin secretion and are risk factors for cardiovascular (CV) events. Thus, targeting normal fasting glucose levels with insulin may reduce CV events.

Insulin Resistance, Inflammation, and Serum Fatty Acid Composition

Top

Fernández-Real J-M, Broch M, Vendrell J, Ricart W. Insulin Resistance, Inflammation, and Serum Fatty Acid Composition. Diabetes Care. 2003;26:1362-1368. Fatty acids (FAs) have been involved in the development of chronic inflammatory conditions such as insulin resistance and obesity. However, the relation among insulin resistance, obesity, inflammatory activity (circulating interleukin [IL]-6) and dietary FAs has been scarcely studied in otherwise healthy subjects.